CMS Targets Leadless Pacers For Medicare Coverage Analysis
This article was originally published in Clinica
Executive Summary
The Medicare agency signaled that it plans to establish a national coverage policy for leadless pacemakers in a memo issued May 18. The memo comes about one month after FDA approved the first such product, Medtronic’s Micra transcatheter leadless single-chamber pacemaker.
You may also be interested in...
Leadless Pacers Would Only Be Covered In Clinical Trials Under Medicare Proposal
The proposed national coverage policy, which was generated from an internal request by the US Medicare agency, would provide Medicare coverage of leadless pacemakers only if they are part of an FDA-approved trial that evaluates peri-procedural complications, post-procedural complications, long-term outcomes, and the influence of patient characteristics on outcomes.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.